How to treat stromal tumors that are resistant to Regorafenib

GIST (GIST) is a rare tumor that usually originates from the stromal cells of the digestive tract or other internal organs. When a patient develops resistance to regorafenib, treatment options depend on the individual circumstances and disease. In addition to regorafenib, there are other targeted drugs that can be used for the treatment of GIST, such as oxitinib, sunitinib, etc. Your doctor may consider whether these drugs are appropriate and make decisions based on genetic mutations and other factors.

For some patients with local progression or few metastases, radiation therapy may be used to control the disease and slow the progression of symptoms. In cases of treatment resistance, symptomatic treatment can help reduce symptoms and improve quality of life. This may include pain management, nutritional support and psychological support, among others. Participation in clinical trials may be an option, especially for new drugs or new treatment options for drug-resistant GIST. Clinical trials can provide more treatment options and opportunities.

RegofenibThe original drug has been launched in China and has entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. SpecificationThe price of each box of 40mg*28 tablets is around RMB 5,000. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The Turkish version of regorafeniboriginal drug specifications 40mg*28 tablets sold overseas is priced around RMB 6,400 per box (the price may fluctuate due to exchange rates). There are also generic regorafenib drugs produced in other countries, and their drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*90 tablets produced by a Bangladesh pharmaceutical factory is around 2,900 yuan (the price may fluctuate due to exchange rates).